Northstrive Biosciences has received preliminary feedback from the FDA on its nonclinical studies and clinical plans for its product, EL-22, intended for use alongside GLP-1 receptor agonists in ...
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.
The FDA has missed the date for Coya Therapeutics’ investigational new drug (IND) application, citing a lack of resources and its current workload as reasons for the delay, according to a legal filing ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address ...
IND Filing and Concurrent RMAT Request Position XytriX™ as a Potential Breakthrough Biotherapeutic for More Than 500 Million People Living with Osteoarthritis Our concurrent request for RMAT ...
The US Food and Drug Administration (FDA) has announced that starting on 1 October 2026, manufacturers must submit adverse ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ESTERO, FL / ACCESS Newswire / January 7, 2026 / Aspire Biopharma ...
MEDIPOST has submitted an investigational new drug (IND) amendment to the US Food and Drug Administration (FDA) to initiate a Phase III trial of its cell therapy for knee osteoarthritis. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results